Market capitalization | $290.65m |
Enterprise Value | $289.77m |
P/E (TTM) P/E ratio | 76.18 |
EV/FCF (TTM) EV/FCF | 27.03 |
EV/Sales (TTM) EV/Sales | 1.84 |
P/S ratio (TTM) P/S ratio | 1.85 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 18.97% |
Revenue (TTM) Revenue | $157.47m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:
6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 157 157 |
19%
19%
|
|
Gross Profit | 141 141 |
9%
9%
|
|
EBITDA | 11 11 |
164%
164%
|
EBIT (Operating Income) EBIT | 9.50 9.50 |
150%
150%
|
Net Profit | 3.88 3.88 |
116%
116%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Raul Rodriguez |
Employees | 147 |
Founded | 1996 |
Website | www.rigel.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.